Article and Video CATEGORIES
Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?
The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?
[powerpress]
Please feel free to offer comments and raise questions in our Discussion Forums.
Tags
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Video
In these videos,
Dr. Jared Weiss gives a brief overview of NUT Carcinoma, discusses treatment options and possible future treatment.
To watch the complete playlist, click here.
Article
Don't let the word "small" deceive you. Small cell lung cancer (SCLC) casts a long shadow, impacting lives with its aggressive nature and the complexities of its treatment. But while the challenges are real, so is the progress. Breakthroughs in small cell lung cancer treatment offer hope. Immunotherapy plus chemo-radiation improves survival by 22 months. Screening catches it early.
Forum Discussions
Can SCLC also be treated with targeted therapy?
Hi amitchouhan,
Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...
I was searching for this, Thank you so much for the info.